Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07513038
PHASE1/PHASE2

Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia

Sponsor: Boston Children's Hospital

View on ClinicalTrials.gov

Summary

Biliary atresia is a rare, progressive liver disease that only affects infants. It leads to complete obstruction and scarring of the bile duct. Current non-invasive diagnostic tests have limited sensitivity. Indocyanine Green (ICG) is a non-radioactive, fluorescent compound with several clinical applications including angiography for ophthalmologic testing, visualization during surgery, and measurement of liver function. After excitation with near infrared light (750-810 nm), ICG emits near infrared light at 850 nm, which can be detected by a special camera. ICG is taken up by the liver exclusively and excreted in the bile, where it is removed from the body in the stool. The hypothesis is that after injection of ICG, participants with biliary atresia will not have any fluorescence detected in the stool. Investigators aim to use ICG as a functional test of bile duct patency in participants with cholestasis being evaluated for biliary atresia.

Key Details

Gender

All

Age Range

0 Days - 3 Months

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2024-08-01

Completion Date

2026-12

Last Updated

2026-04-06

Healthy Volunteers

No

Conditions

Interventions

DRUG

Indocyanine Green (ICG)

One time Indocyanine Green (ICG) injection.

Locations (1)

Boston Children's Hospital

Boston, Massachusetts, United States